|
|
|
|
|
|
| |
|
Newsletter Sponsor
|
|
Not all Cyclodextrins are created equally
Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including uding Gilead’s VEKLURY®, Amgen’s KYPROLIS®, Baxter International’s NEXTERONE®, Acrotech Biopharma L.L.C.’s and CASI Pharmaceuticals’ EVOMELA®, Melinta Therapeutics’ BAXDELA™.
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
 |
Events |
 |
|
| |
|
|
Excipient World 2021
National Harbor, MD – 09/27/2021
Excipient World is the leading education, networking and sourcing resource for the $6+ billion and growing global excipient market. It’s the ONLY U.S....
event details » |
 |
|
|
|
|
9th Annual Immuno-Oncology Summit
Westin Copley Place, Boston, MA & Online – 10/04/2021
Over the past 9 years, CHI's Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing ...
event details » |
|
|
|
 |
|
|
